Graft versus host disease · 6 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ibrutinib monotherapy Variant #01 | — | R 81 964 | 28d | ~41.3 mo | ~30.3 mo | ~2 | ~R 163 929 PFS proxy · indirect | 17 |
Prednisone monotherapy Variant #11 Partial | — | R 138 | 7d | ~2.2 mo | ~14.1 mo | ~1 | ~R 138 PFS proxy · indirect | 8 |
Cyclosporine, Corticosteroids, Rituximab Variant #01 | — | — | 56d | — | — | — | — | — |
Cyclosporine and Prednisone Variant #01 | — | — | 56d | — | — | — | — | — |
Cyclosporine, Sirolimus, Prednisone Variant #01 | — | — | — | — | — | — | — | — |
Sirolimus, Tacrolimus, Prednisone Variant #01 | — | — | — | — | — | — | — | — |
6 of 6 regimens shown